A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park S.H. | - |
dc.contributor.author | Jeen Y.T. | - |
dc.contributor.author | Chun H.R. | - |
dc.contributor.author | Kim D.I. | - |
dc.contributor.author | Baeck C.W. | - |
dc.contributor.author | Kim Y.S. | - |
dc.contributor.author | Chun H.J. | - |
dc.contributor.author | Lee H.S. | - |
dc.contributor.author | Um S.H. | - |
dc.contributor.author | Choi J.H. | - |
dc.contributor.author | Kim C.D. | - |
dc.contributor.author | Ryu H.S. | - |
dc.contributor.author | Hyun J.H. | - |
dc.date.available | 2020-11-03T16:47:13Z | - |
dc.date.issued | 2005-10 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.issn | 2233-6869 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/20057 | - |
dc.description.abstract | Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission. | - |
dc.format.extent | 5 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.title | A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.scopusid | 2-s2.0-33644921817 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology, v.46, no.4, pp 297 - 301 | - |
dc.citation.title | The Korean journal of gastroenterology | - |
dc.citation.volume | 46 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 297 | - |
dc.citation.endPage | 301 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART000973748 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | gastrointestinal agent | - |
dc.subject.keywordPlus | infliximab | - |
dc.subject.keywordPlus | monoclonal antibody | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | case report | - |
dc.subject.keywordPlus | child | - |
dc.subject.keywordPlus | Crohn disease | - |
dc.subject.keywordPlus | drug administration | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | intravenous drug administration | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | Antibodies, Monoclonal | - |
dc.subject.keywordPlus | Child | - |
dc.subject.keywordPlus | Crohn Disease | - |
dc.subject.keywordPlus | Drug Administration Schedule | - |
dc.subject.keywordPlus | Gastrointestinal Agents | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Infusions, Intravenous | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordAuthor | Crohn's disease | - |
dc.subject.keywordAuthor | Pediatrics | - |
dc.subject.keywordAuthor | Infliximab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.